Skip to main content
Sign In
 

Recent Publications


Aberrant Mer receptor tyrosine kinase expression contributes to leukemogenesis in acute myeloid leukemia.
Lee-Sherick AB, Eisenman KM, Sather S, McGranahan A, Armistead PM, McGary CS, Hunsucker SA, Schlegel J, Martinson H, Cannon C, Keating AK, Earp HS, Liang X, DeRyckere D, Graham DK.
Oncogene. 2013 Nov 14;32(46):5359-68. Epub 2013 Mar 11


UNC569, a Novel Small-Molecule Mer Inhibitor with Efficacy against Acute Lymphoblastic Leukemia In Vitro.
Christoph S, DeRyckere D, Schlegel J, Frazer JK, Batchelor LA, Trakhimets AY, Sather S, Hunter DM, Cummings CT, Lui J, Yang C, Kireev D, Simpson C, Norris-Drouin J, Hull-Ryde EA, Janzen WP, Johnson GL, Wang X, Frye SV, Earp HS, Graham DK.
Mol Cancer Ther. 2013 Nov;12(11):2367-77. Epub 2013 Aug 30


Mer receptor tyrosine kinase is a therapeutic target in pre-B cell acute lymphoblastic leukemia.
Linger RM, Lee-Sherick AB, DeRyckere D, Cohen RA, Jacobsen KM, McGranahan A, Brandao LN, Sawczyn KK, Liang X, Keating AK, Tan AC, Earp HS, Graham DK.
Blood. 2013 Jul 16, [epub ahead of print]


MerTK inhibition in tumor leukocytes decreases tumor growth and metastasis.
Cook RS, Jacobsen KM, Wofford AM, DeRyckere D, Stanford J, Prieto AL, Redente E, Sandahl M, Hunter DM, Strunk KE, Graham DK, Earp HS.
J Clin Invest. 2013 Jul 8, [epub ahead of print]


Molecular Pathways: MERTK Signaling in Cancer.
Cummings C, DeRyckere D, Earp HS, Graham DK
Clin Cancer Res. 2013 July 5, [epub ahead of print]


MERTK receptor tyrosine kinase is a therapeutic target in melanoma.
Schlegel J, Sambade MJ, Sather S, Moschos SJ, Tan AC, Winges A, DeRyckere D, Carson CC, Trembath DB, Tentler JJ, Eckhardt SG, Kuan PR, Hamilton RL, Duncan LM, Miller CR, Nikolaishvili-Feinberg N, Midkiff BR, Lui J, Zhang W, Yang C, Wang X, Frye SV, Earp HS, Shields JM, Graham DK.
J Clin Invest. 2013 May 1;123(5)


Inhibition of MerTK increases chemosensitivity and decreases oncogenic potential in T-cell acute lymphoblastic leukemia.
Brandao LN, Winges A, Christoph S, Sather S, Migdall-Wilson J, Schlegel J, McGranahan A, Gao D, Liang X, DeRyckere D, Graham DK
Blood Cancer J. 2013 Jan 25;3:e101


Bioluminescence imaging of leukemia cell lines in vitro and in mouse xenografts: effects of monoclonal and polyclonal cell populations on intensity and kinetics of photon emission.
Christoph S, Schlegel J, Alvarez-Calderon F, Kim YM, Brandao LN, DeRyckere D, Graham DK.
J Hematol Oncol. 2013 Jan 23;6:10


Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human non-small cell lung cancer.
Linger RM, Cohen RA, Cummings CT, Sather S, Migdall-Wilson J, Middleton DH, Lu X, Baron AE, Franklin WA, Merrick DT, Jedlicka P, DeRyckere D, Heasley LE, Graham DK.
Oncogene. 2012 Aug 13


Prolonged exposure to a Mer ligand in leukemia: Gas6 favors expression of a partial Mer glycoform and reveals a novel role for Mer in the nucleus.
Migdall-Wilson J, Bates C, Schlegel J, Brandao L, Linger RM, DeRyckere D, Graham DK.
PLoS One. 2012;7(2):e31635